Download PDF

1. Company Snapshot

1.a. Company Description

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need.It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma.The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate.


It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer.The company was formerly known as Nanopharma Corp.and changed its name to Mersana Therapeutics, Inc.


in November 2005.Mersana Therapeutics, Inc.was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Show Full description

1.b. Last Insights on MRSN

Mersana Therapeutics' recent performance was negatively impacted by a lack of significant clinical trial updates and no major product approvals. The company's Q4 earnings beat was overshadowed by the absence of substantial pipeline progress. Additionally, the recent announcement of an upcoming oral presentation of Emi-Le clinical data at the ESMO Breast Cancer 2025 Annual Congress, while potentially positive, is a long-term development that may not have a significant short-term impact on the company's performance.

1.c. Company Highlights

2. Mersana Therapeutics' Emi-Le Shows Promise in TNBC, But Financials Raise Concerns

Mersana Therapeutics reported a loss per share of $4.08, worse than the estimated loss of $3.75. The company's cash and cash equivalents stood at $77 million as of the end of the second quarter, which is expected to support their current operating plan commitments into mid-2026. Revenue growth is estimated to be 64.8% next year, indicating a potential surge in the company's top line.

Publication Date: Aug -23

📋 Highlights
  • Emi-Le ORR in TNBC and ACC1:: 31% confirmed objective response rate in B7-H4 high TNBC patients, 56% in adenoid cystic carcinoma type 1 (ACC1) patients.
  • Phase I Expansion Enrollment:: Over 45 patients enrolled in dose expansion for post-topo-1 TNBC, with two dosing regimens under investigation.
  • Financial Position:: $77 million in cash and cash equivalents as of Q2 2025, projected to fund operations through mid-2026.
  • Fast Track Designation:: Covers post-topo breast cancer, including HER2 low patients, with potential for broader population trials.
  • Proteinuria Mitigation Strategy:: Ongoing at dose B with investigator enthusiasm; data expected to show if prophylaxis extends therapy duration.

Financial Performance and Expectations

The company's financial performance was marked by a significant loss per share, highlighting the challenges faced by biotech companies in the development stage. With a P/S Ratio of 1.11, the market appears to be pricing in a relatively modest growth expectation, considering the potential of Emi-Le in the treatment of TNBC. The EV/EBITDA ratio of 0.39 suggests that the company's enterprise value is not excessively high relative to its EBITDA, although the negative EBITDA indicates that the company is not yet profitable.

Emi-Le's Progress in TNBC

Emi-Le, Mersana's lead product candidate, demonstrated a 31% confirmed objective response rate (ORR) in patients with B7-H4 high tumor expression and a 56% ORR in patients with adenoid cystic carcinoma type 1 (ACC1). The company has initiated a dose expansion phase of their Phase I clinical trial, enrolling patients with TNBC who have received 1 to 4 prior lines of treatment. As Dr. Marty Huber noted, the post-topo-1 TNBC opportunity is sizable, with the potential to grow substantially larger.

Valuation and Growth Prospects

With a ROE of 320.25%, Mersana's return on equity is unusually high, although this is likely due to the company's significant losses. The Net Debt / EBITDA ratio of 1.24 indicates that the company's debt is relatively manageable compared to its EBITDA, although the negative EBITDA again complicates this interpretation. As the company continues to progress with Emi-Le's development, investors will be watching for updates on the dose expansion phase and the potential for a Phase III study in TNBC.

Future Outlook

Mersana's focus on TNBC and potential expansion into other breast cancer indications, including hormone receptor-positive breast cancer, suggests that the company has a robust pipeline. The Fast Track designation for Emi-Le in post-topo breast cancer, which includes HER2 low patients, could allow for a broader patient population and potentially accelerate the approval process. As enrollment continues in the dose expansion phase, the company is expected to share data later this year, which should provide further insight into the efficacy of Emi-Le.

3. NewsRoom

Card image cap

HAPPY THANKSGIVING AND ALERT: The M&A Class Action Firm Continues to Investigate the Merger – EXAS, SEE, CDTX, and MRSN

Nov -27

Source: globenewswire.com

Card image cap

Halper Sadeh LLC Encourages CDTX, MRSN, HOLX Shareholders to Contact the Firm to Discuss Their Rights

Nov -14

Source: prnewswire.com

Card image cap

Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates

Nov -14

Source: zacks.com

Card image cap

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Mersana Therapeutics, Inc. (NASDAQ: MRSN)

Nov -13

Source: globenewswire.com

Card image cap

Mersana Therapeutics, Inc. (MRSN) M&A Call Transcript

Nov -13

Source: seekingalpha.com

Card image cap

Shareholder Alert: The Ademi Firm investigates whether Mersana Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

Nov -13

Source: prnewswire.com

Card image cap

Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout

Nov -13

Source: benzinga.com

Card image cap

MRSN Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Mersana Therapeutics, Inc. is Fair to Shareholders

Nov -13

Source: businesswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.85%)

6. Segments

Antibody Drug Conjugate

Expected Growth: 10.85%

Mersana Therapeutics' Antibody Drug Conjugate (ADC) growth is driven by increasing adoption in cancer treatment, strong clinical trial results, and partnerships with leading pharma companies. The ADC's targeted therapy approach and potential to replace traditional chemotherapy are key growth catalysts, with the global ADC market expected to reach $15.6 billion by 2027.

7. Detailed Products

Dolasynthen

A novel antibody-drug conjugate (ADC) platform that utilizes a proprietary dolaflexin payload to target cancer cells

XMT-1536

A Dolaflexin-based ADC targeting NaPi2b, a highly expressed antigen in ovarian cancer

XMT-1592

A B7-H3 targeting ADC utilizing the Dolaflexin payload

Dolaflexin-based ADCs

A platform of ADCs utilizing the Dolaflexin payload to target various cancer antigens

8. Mersana Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Mersana Therapeutics, Inc. operates in a highly competitive industry, but the threat of substitutes is mitigated by the company's focus on developing novel antibody-drug conjugates.

Bargaining Power Of Customers

Mersana Therapeutics, Inc. has a diverse customer base, and no single customer accounts for a significant portion of revenue, reducing the bargaining power of customers.

Bargaining Power Of Suppliers

Mersana Therapeutics, Inc. relies on a few key suppliers for raw materials and services, but the company's strong relationships with these suppliers mitigate the bargaining power of suppliers.

Threat Of New Entrants

The biotechnology industry is highly competitive, and new entrants can easily disrupt the market, posing a significant threat to Mersana Therapeutics, Inc.'s market share.

Intensity Of Rivalry

The biotechnology industry is highly competitive, and Mersana Therapeutics, Inc. faces intense rivalry from established companies and new entrants, making it challenging to maintain market share.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 43.68%
Debt Cost 11.88%
Equity Weight 56.32%
Equity Cost 11.88%
WACC 11.88%
Leverage 77.57%

11. Quality Control: Mersana Therapeutics, Inc. passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Fennec Pharmaceuticals

A-Score: 6.0/10

Value: 8.2

Growth: 8.6

Quality: 6.4

Yield: 0.0

Momentum: 10.0

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
Synlogic

A-Score: 4.8/10

Value: 7.2

Growth: 5.6

Quality: 4.8

Yield: 0.0

Momentum: 8.5

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
Dyadic International

A-Score: 4.5/10

Value: 8.2

Growth: 5.0

Quality: 4.6

Yield: 0.0

Momentum: 8.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
GlycoMimetics

A-Score: 3.7/10

Value: 6.2

Growth: 4.6

Quality: 3.3

Yield: 0.0

Momentum: 6.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Mersana Therapeutics

A-Score: 3.4/10

Value: 9.2

Growth: 4.8

Quality: 5.8

Yield: 0.0

Momentum: 0.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Genelux

A-Score: 3.2/10

Value: 6.0

Growth: 4.2

Quality: 3.6

Yield: 0.0

Momentum: 4.5

Volatility: 0.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

27.89$

Current Price

27.89$

Potential

-0.00%

Expected Cash-Flows